Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392084 | 0.83 | MAOB (0.52) | MAOBBACE1TTREGFRHSD17B10 | |
| SCHEMBL8296534 | 0.83 | MAOB (0.57) | MAOBBACE1TTRTAAR1MEN1 | |
| SCHEMBL16625523 | 0.83 | MAOB (0.52) | MAOBBACE1TTREGFRHSD17B10 | |
| SCHEMBL4847162 | 0.83 | MAOB (0.52) | MAOBBACE1TTREGFRHSD17B10 | |
| SCHEMBL8319257 | 0.82 | MAOB (0.50) | MAOBBACE1TTRTAAR1EGFR | |
| Hydroquinone SCHEMBL9788450 | 0.82 | MAOB (0.50) | MAOBBACE1TTREGFRHSD17B10 | |
| SCHEMBL13567696 | 0.82 | MAPT (0.47) | HSD17B10KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL696593 | 0.81 | BACE1 (0.47) | MAOBBACE1TTREGFRHSD17B10 | |
| SCHEMBL4434341 | 0.81 | BACE1 (0.48) | MAOBBACE1EGFRKDM4EL3MBTL1 | |
| SCHEMBL29582819 | 0.81 | ALOX5 (0.58) | MAOBTTRMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761083-B | 5-HT for treating depression 2A Agonists | 罗福拉公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| CN-114761083-A | 5-HT for the treatment of depression2AAgonists | 罗福拉公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| EP-1092721-B1 | Chiral glucosides and their use as chiral dopants for the production of cholesteric liquid crystalline compositions | BASF AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
| US-4684649-A | IMPROVING EFFICIENCY OF FEEDS | MAROTTA ENRICO (IT) | 1987-08-04 | — | — | US | disclosed |
| EP-0192992-A2 | Quinoxaline derivatives useful for treatment and prophilaxis of swine dysentery and as animal growth promotants | Marotta, Enrico (IT) | 1986-09-03 | — | — | EP | disclosed |
| CN-86101225-A | Process for the preparation of quinazoline derivatives as growth promoters for animals for the treatment and prophylaxis of swine dysentery | — | 1986-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | MAOB 74/4885BACE1 3577/4885TTR 4027/4885 |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | MAOB 74/4885BACE1 3577/4885TTR 4027/4885 |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | MAOB 74/4885BACE1 3577/4885TTR 4027/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | MAOB 4333/4885BACE1 4250/4885TTR 4736/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | MAOB 2142/4885BACE1 3606/4885TTR 2771/4885 |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | MAOB 74/4885BACE1 3577/4885TTR 4027/4885 |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | MAOB 74/4885BACE1 3577/4885TTR 4027/4885 |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | MAOB 74/4885BACE1 3577/4885TTR 4027/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | MAOB 4814/4885BACE1 868/4885TTR 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.